MK-0752

DRUG4 trials

Sponsors

Pediatric Brain Tumor Consortium, Loyola University, Merck Sharp & Dohme LLC

Conditions

Advanced CancerBrain and Central Nervous System TumorsBreast CancerNeoplasms Malignant

Phase 1

MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer

TerminatedNCT00572182

Pediatric Brain Tumor ConsortiumBrain and Central Nervous System Tumors

Start: 2008-07-31End: 2011-02-28Updated: 2012-03-06

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

TerminatedNCT01243762

Merck Sharp & Dohme LLCNeoplasms Malignant

Start: 2010-11-22End: 2013-03-25Updated: 2018-08-16

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

CompletedNCT01295632

Merck Sharp & Dohme LLCAdvanced Cancer

Start: 2011-02-28End: 2015-08-31Updated: 2015-08-27

Phase 4

Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer

CompletedNCT00756717

Loyola UniversityBreast Cancer

Start: 2008-02-14End: 2011-12-21Updated: 2019-09-04

Related Papers

Abstract P5-04-10: The role of DAXX on enrichment of breast cancer stem cells from ER+ breast cancer

Cancer Research2019-02-15

Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.

2015-07-1860 citations

Abstract S4-03: Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model

Cancer Research2015-05-012 citations

Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer.

Journal of Clinical Oncology2014-05-202 citations

Results of a phase I trial combining ridaforolimus (mTOR inhibitor) and MK-0752 (Notch inhibitor) in patients with advanced solid tumors.

Journal of Clinical Oncology2014-05-20